Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsKevin Sevarino, MD
Associate Clinical ProfessorAbout
Copy Link
Appointments
Education & Training
- MD
- McGill University (1982)
Research
Copy Link
Research at a Glance
Yale Co-Authors
Frequent collaborators of Kevin Sevarino's published research.
Publications Timeline
A big-picture view of Kevin Sevarino's research output by year.
Richard Goodman
Ned Cooney, PhD
Erin O'Brien, PsyD
Jane Jane, PhD
John Krystal, MD
Ralitza Gueorguieva, PhD
52Publications
4,346Citations
Publications
2024
Disorders due to Substance Use: Stimulants
Sevarino K, Farrell M. Disorders due to Substance Use: Stimulants. 2024, 2843-2932. DOI: 10.1007/978-3-030-51366-5_26.Peer-Reviewed Original ResearchCitationsConceptsBody of preclinical researchAssociated with significant impairmentStimulant use disorderFDA-approved medicationsBehavioral therapyOccupational functioningUse disorderPrescribed stimulantsSignificant impairmentHepatitis CClinical featuresSubstance usePharmacological therapyMedical illnessPreclinical researchRates of overdose deathsCardiovascular diseaseDisordersElevated ratesElevated riskTherapyPotential targetOverdose deathsStimulationAdverse consequences
2023
Disorders Due to Substance Use: Stimulants
Sevarino K, Farrell M. Disorders Due to Substance Use: Stimulants. 2023, 1-90. DOI: 10.1007/978-3-030-42825-9_26-1.Peer-Reviewed Original ResearchCitationsConceptsBody of preclinical researchAssociated with significant impairmentStimulant use disorderFDA-approved medicationsBehavioral therapyOccupational functioningUse disorderPrescribed stimulantsSignificant impairmentHepatitis CClinical featuresSubstance usePharmacological therapyMedical illnessPreclinical researchRates of overdose deathsCardiovascular diseaseDisordersElevated ratesElevated riskTherapyPotential targetOverdose deathsStimulationAdverse consequences
2017
Mecamylamine treatment for alcohol dependence: a randomized controlled trial
Petrakis IL, Ralevski E, Gueorguieva R, O'Malley SS, Arias A, Sevarino KA, Jane JS, O'Brien E, Krystal JH. Mecamylamine treatment for alcohol dependence: a randomized controlled trial. Addiction 2017, 113: 6-14. PMID: 28710873, PMCID: PMC5725262, DOI: 10.1111/add.13943.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHeavy drinking daysDrinking daysAlcohol use disorderUse disordersAlcohol consumptionAlcohol dependenceDouble-blind clinical trialNicotinic acetylcholine receptor antagonistWeeks of treatmentAcetylcholine receptor antagonistCurrent alcohol dependenceSignificant differencesTreatment-seeking smokersMecamylamine treatmentPlacebo groupMonth 3Primary outcomeSmoking statusNicotine withdrawalReceptor antagonistNovel pharmacotherapiesClinical trialsManagement therapyMecamylamineTreatment groups
2016
A Randomized Trial of Contingency Management for Smoking Cessation During Intensive Outpatient Alcohol Treatment
Cooney JL, Cooper S, Grant C, Sevarino K, Krishnan-Sarin S, Gutierrez IA, Cooney NL. A Randomized Trial of Contingency Management for Smoking Cessation During Intensive Outpatient Alcohol Treatment. Journal Of Substance Use And Addiction Treatment 2016, 72: 89-96. PMID: 27542442, DOI: 10.1016/j.jsat.2016.07.002.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsEnd of treatmentNicotine replacement therapyOutpatient alcohol treatmentContingency managementReplacement therapyDependent smokersQuit ratesAbstinence outcomesAlcohol treatmentEfficacy of CMEvidence-based smoking cessation treatmentOutpatient alcohol treatment programOne monthAlcohol-dependent smokersInitial smoking abstinenceSmoking cessation treatmentDrug use outcomesAlcohol treatment programsCognitive behavioral therapyCognitive behavior therapyCessation treatmentRandomized trialsSmoking cessationSmoking abstinenceClinical trials
2015
Concurrent Alcohol and Tobacco Treatment: Effect on Daily Process Measures of Alcohol Relapse Risk
Cooney NL, Litt MD, Sevarino KA, Levy L, Kranitz LS, Sackler H, Cooney JL. Concurrent Alcohol and Tobacco Treatment: Effect on Daily Process Measures of Alcohol Relapse Risk. Journal Of Consulting And Clinical Psychology 2015, 83: 346-358. PMID: 25622198, PMCID: PMC4380705, DOI: 10.1037/a0038633.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSmoking cessation interventionSmoking treatmentCessation interventionsSmoking abstinenceProcess measuresAlcohol treatmentOutpatient alcohol treatment programAlcohol-dependent smokersDaily smoking abstinenceAlcohol relapse riskOutpatient alcohol treatmentLow alcohol consumptionAlcohol treatment programsDependent smokersRelapse riskAlcohol abstinenceWaiting listInteractive voice response systemSmoking outcomesAlcohol consumptionCSC participantsVoice response systemIVR assessmentsTreatment programDaily assessmentStimulant Use Disorders
Sevarino K, Shelby B. Stimulant Use Disorders. 2015, 1561-1614. DOI: 10.1002/9781118753378.ch80.Peer-Reviewed Original ResearchConceptsStimulant use disorderUse disordersMonths of treatmentOngoing psychosocial stressorsSubstance abuse treatmentCocaine use disorderDisease courseAcute cravingAppropriate treatmentHigh riskPsychosocial stressorsAbuse treatmentNonmedical useCrystal methamphetamineDrug abuseDisordersMethamphetamineTreatmentPrescription stimulantsAmphetamineStimulantsPatientsRelapseDextroamphetamineMethylphenidate
2009
Smoking cessation during alcohol treatment: a randomized trial of combination nicotine patch plus nicotine gum
Cooney NL, Cooney JL, Perry BL, Carbone M, Cohen EH, Steinberg HR, Pilkey DT, Sevarino K, Oncken CA, Litt MD. Smoking cessation during alcohol treatment: a randomized trial of combination nicotine patch plus nicotine gum. Addiction 2009, 104: 1588-1596. PMID: 19549054, PMCID: PMC2753831, DOI: 10.1111/j.1360-0443.2009.02624.x.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsActive nicotine patchNicotine patchPlacebo gumNicotine gumSmoking cessationDouble-blind placebo-controlled clinical trialAlcohol treatmentPlacebo-controlled clinical trialBetter smoking outcomesCombination nicotine patchTransdermal nicotine patchDouble-blind conditionsSubstance abuse clinicsMonthly booster sessionsCombination nicotine replacementNicotine replacementCessation treatmentTobacco smokersLarge trialsCombination therapyMore cigarettesMedication conditionActive gumClinical trialsBooster sessionsNaltrexone for Initiation and Maintenance of Opiate Abstinence
Sevarino K, Kosten T. Naltrexone for Initiation and Maintenance of Opiate Abstinence. Contemporary Neuroscience 2009, 227-245. DOI: 10.1007/978-1-59745-197-0_12.Peer-Reviewed Original ResearchCitationsAltmetricConceptsPartial opioid agonist buprenorphineDistinct pharmacological classesOpiate agonist methadoneRole of naltrexoneOpioid antagonist naltrexoneAntagonist naltrexoneOpiate dependencePharmacological classesOpiate abstinenceAbstinent statePhysical dependenceLong-term maintenanceNaltrexoneOpiatesBuprenorphinePharmacotherapyMethadoneAbstinence
2008
Substance Abuse: Amphetamine Use Disorders
Sevarino K. Substance Abuse: Amphetamine Use Disorders. 2008, 1005-1018. DOI: 10.1002/9780470515167.ch55.Peer-Reviewed Original Research
2005
Efficacy of dose and contingency management procedures in LAAM-maintained cocaine-dependent patients
Oliveto A, Poling J, Sevarino K, Gonsai K, McCance-Katz E, Stine S, Kosten T. Efficacy of dose and contingency management procedures in LAAM-maintained cocaine-dependent patients. Drug And Alcohol Dependence 2005, 79: 157-165. PMID: 16002025, DOI: 10.1016/j.drugalcdep.2005.01.007.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsHC groupOpioid useContingency management proceduresCocaine useEfficacy of DoseOverall opioid useOpioid withdrawal symptomsHigh-dose groupLow-dose groupLY groupDrug-free urineCocaine-dependent patientsCocaine-dependent participantsBaseline characteristicsMaintenance doseWithdrawal symptomsClinical trialsCocaine abstinenceOpioidsLAAMUrine samplesHY groupAbstinenceDoseUrine